TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart™

New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel…

TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Breast and Ovarian Cancer

SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer. Folate receptor alpha is expressed…

TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer

Results Meet Management’s Highest Expectations SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes.…

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress

SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders. Dear Shareholders, Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it. To address this, we now announce the completion…

Tapimmune Announces Development Of Advanced Immunotherapeutic Vaccine Expression And Delivery System

TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system. The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be…

TapImmune Provides Operational Update including Human Data Supporting Use of TAP Based Cancer Vaccine Company Establishes Laboratory Facilities in Vancouver Canada

ANCOUVER, Canada, 31 July, 2007 – TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laboratory facilities and provides this update to shareholders. The opening of the new laboratory facility in Vancouver facilitates the transfer of its technology from The University of British Columbia…